Gujarat Kidney appoints Dr Disha Bharpoda as independent director
Appointed Mrs Disha Bharpoda as additional non-executive independent director. Term is five years starting August 24, 2026, subject to AGM approval. Mrs Bharpoda has an MD in Radiology and runs her own centre. Board noted shareholder approval for IPO proceeds utilisation variation.

*this image is generated using AI for illustrative purposes only.
Gujarat Kidney and Super Speciality appointed Mrs Disha Bharpoda as an additional non-executive independent director on August 24, 2026. The appointment follows a recommendation from the Nomination and Remuneration Committee and is subject to shareholder approval at the next annual general meeting.
The Board of Directors approved the appointment during its meeting held on August 24, 2026. Mrs Bharpoda will serve a first term of five consecutive years. She is not liable to retire by rotation.
Director Profile
Mrs Bharpoda holds an MD in Radiology from Baroda Medical College, Maharaja Sayajirao University, Vadodara, completed in 2021. Her professional background includes five years as a senior resident doctor. She subsequently established her own radiology centre.
The filing confirms that Mrs Bharpoda has no relationship with any existing director of the company.
Other Board Approvals
The board also took note of the approval given by shareholders via postal ballot for a special resolution. This resolution concerns the variation in the objects or terms of utilisation of the initial public offering proceeds.
The meeting commenced at 4:30 pm and concluded at 5 pm. Pragnesh Bharpoda, managing director, signed the disclosure filed with the BSE and NSE.
Historical Stock Returns for Gujarat Kidney and Super Speciality
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.28% | +11.81% | +17.46% | +36.35% | +45.92% | +45.92% |
How might Mrs. Bharpoda's specialized background in radiology influence Gujarat Kidney and Super Speciality's strategic expansion into diagnostic imaging services?
What specific changes to the IPO proceeds utilization are implied by the approved special resolution, and how will this reallocation impact the company's near-term capital expenditure?
Could the appointment of an independent director with a medical background signal a shift in corporate governance priorities towards clinical quality assurance or patient care standards?


































